Stockreport

Verastem Oncology Announces Presentation of Updated Duvelisib Combination Clinical Data in Peripheral T-Cell Lymphoma at the American Society of Hematology 2018 Annual Meeting

Verastem, Inc.  (VSTM) 
Last verastem, inc. earnings: 10/29 04:17 pm Check Earnings Report
US:NASDAQ Investor Relations: verastem.com
PDF Combination of Duvelisib and Romidepsin Resulting in a 59% Overall Response Rate in Relapsed or Refractory Peripheral T-Cell Lymphoma BOSTON--(BUSI [Read more]